Hosted on MSN8d
Bottom 100 Stocks to Buy: Is B. Riley Financial Uninvestable?
The markets were closed on Monday for Martin Luther King Jr. Day, which also marked the inauguration of Donald J. Trump, the ...
B.Riley sets Foghorn stock Buy rating, $10 target
The recent decline in Foghorn Therapeutics' stock was attributed to the discontinuation of another of its products, FHD-286. However, the analysts emphasized that this event does not impact their ...
B. Riley upgrades Redwire on growth potential from Edge Autonomy acquisition
Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.
FY2024 EPS Estimates for Ladder Capital Cut by B. Riley
Analysts at B. Riley reduced their FY2024 earnings estimates for shares of Ladder Capital in a research report issued to clients and investors on Monday, January 27th. B. Riley analyst R. Binner now ...
ClearPoint Neuro price target raised to $20 from $15 at B. Riley
B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...
B.Riley Financial Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...
Logility downgraded to Neutral from Buy at B. Riley
B. Riley analyst Zach Cummins downgraded Logility (LGTY) to Neutral from Buy with a $14.30 price target after Aptean, Insight Partners, ...